Database : MEDLINE
Search on : Kidney and Neoplasms [Words]
References found : 95770 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 9577 go to page                         

  1 / 95770 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29505538
[Au] Autor:Zhu J; Li H; Ding L; Cheng H
[Ad] Address:Department of Radiology.
[Ti] Title:Imaging appearance of renal epithelioid angiomyolipoma: A case report and literature review.
[So] Source:Medicine (Baltimore);97(1):e9563, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Epithelioid angiomyolipoma (EAML) is an extremely rare disease. It commonly occurs in middle-aged females and mainly involves the kidney. Histological and immunohistochemical examination play important roles in differentiating EAML from renal cell carcinoma (RCC) and poor-fat angiomyolipoma (AML). PATIENT CONCERNS: Here, We report the imaging phenotype, as well as the pathological findings of a case of EAML in a 39-year-old female. DIAGNOSES: Preoperative noncontrast computed tomography (CT) scan revealed a 6.0 × 5.2 × 7.0 cm soft tissue mass with necrosis, located in the left kidney. On contrast-enhanced CT images, aprogressive enhancement pattern was observed. CT angiography did not show any enlarged vessels or vascular malformation. Abdominal MRI showed a well-circumscribed solid mass with a heterogeneous signal on T1-weighted and T2-weighted images. Ultrasonography of the abdomen demonstrated a hypoechoic mass with abundant blood flow. This patient underwent radical nephrectomy. The pathologic diagnosis was EAML. INTERVENTIONS: This patient underwent operative resection of the tumor. The resection margins were negative for the neoplastic proliferation and no distant metastases were found. The patient did not receive advanced radiotherapy or chemotherapy. OUTCOMES: Four months after surgery, the follow-up CT scan did not reveal any local recurrence or distant metastases. LESSONS: This case adds to the experience with EAML by summarizing its imaging characteristics as well as reviewing the literature. Additionally, we described the state-of-the-art management of the management of this rare tumor.
[Mh] MeSH terms primary: Angiomyolipoma/diagnostic imaging
Kidney Neoplasms/diagnostic imaging
[Mh] MeSH terms secundary: Adult
Angiomyolipoma/pathology
Female
Humans
Kidney/pathology
Kidney Neoplasms/pathology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009563

  2 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376614
[Au] Autor:Popkov VM; Tarasenko AI; Maslyakova GN; Rossolovskii AN; Berezinets OL
[Ad] Address:Saratov State Medical University n. a. V. I. Razumovsky, Saratov, Russia.
[Ti] Title:[A look at the problem of surgical treatment of renal cel carcinoma in the aspect of biomolecular diagnosis and assessment of renal function].
[So] Source:Urologiia;(6):153-159, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:The article reviews the domestic and international literature on the issues of biomolecular diagnosis of acute renal injury in the perioperative period in patients with renal cell carcinoma (RCC). Emerging opportunities for early detection of tumors make even more relevant the use of minimally invasive interventions. Of equal importance is the assessment of renal function in patients with diagnosed RCC and the prediction of acute renal injury and progression of chronic kidney disease in the postoperative period. The authors performed a systematic search for preclinical and clinical studies to identify the main trends and achievements in the field of biomolecular diagnosis of RCC and renal injury allowing the individual approach to choosing surgical treatment, improve the survival and quality of life of the patient and improve the functional state of the renal parenchyma.
[Mh] MeSH terms primary: Carcinoma, Renal Cell
Kidney Neoplasms
Laparoscopy/methods
Nephrectomy/methods
[Mh] MeSH terms secundary: Carcinoma, Renal Cell/diagnosis
Carcinoma, Renal Cell/metabolism
Carcinoma, Renal Cell/surgery
Humans
Kidney Neoplasms/diagnosis
Kidney Neoplasms/metabolism
Kidney Neoplasms/surgery
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  3 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376604
[Au] Autor:Guliev BG; Yagubov KK
[Ad] Address:Department of Urology, I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russia.
[Ti] Title:[Laparoscopic transperitoneal partial nephrectomy for a tumor of the upper segment].
[So] Source:Urologiia;(6):96-100, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:INTRODUCTION: Laparoscopic resection of upper pole kidney tumors is a technically challenging procedure. When tumors are located on the dorsal side of the kidney, the renal-rotation technique may facilitate laparoscopic partial nephrectomy. AIM: To present the technique and results of laparoscopic partial nephrectomy (LPN) for tumors of the upper pole of the kidney with its rotation around the renal hilum. MATERIAL AND METHODS: The study presents a retrospective analysis of the results of 12 patients who underwent LPN for upper pole kidney tumors using the renal-rotation technique. The kidney with the renal hilar vessels and the upper third of the ureter were mobilized using a transperitoneal access. Then the kidney was rotated over its pedicular axis so that the upper pole was located inferiorly. As a result, the posterior upper pole tumor was located anteriorly, thereby facilitating its resection. After removing the tumor and confirming homeostasis, the kidney was returned to its original position. RESULTS: The results of LPN using this technique were successful in all 12 patients. The mean operative time was 120+/-35.0 (90-210) min, the warm ischemia time was 14.5+/-7.8 (10-26) min, and the blood loss was 120.0+/-65.5 (60-300) ml. The intraoperative complication occurred in 1 (8.3%) patients, postoperative complications were observed in 3 patients. Histopathology showed that 11 (91.7%) patients had renal cell carcinoma and one (8.3%) had angiomyolipoma. Analysis of early (18.6+/-5.0 months) oncological outcomes showed no local recurrence and distant metastases. CONCLUSION: With dorsally located upper pole kidney tumors, the renal-rotation technique facilitates the performance of LPN and minimizes the risk of intra- and postoperative complications. This method requires the maximum mobilization of the kidney along with the renal hilar vessels and the upper third of the ureter to rotate it for optimal resection conditions.
[Mh] MeSH terms primary: Kidney Neoplasms/surgery
Laparoscopy/methods
Nephrectomy/methods
Warm Ischemia/methods
[Mh] MeSH terms secundary: Aged
Female
Humans
Kidney Neoplasms/diagnostic imaging
Male
Middle Aged
Tomography, X-Ray Computed
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  4 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376603
[Au] Autor:Komyakov BK; Guliev BG; Novikov AI; Yagubov KK
[Ad] Address:Department of Urology, I.I. Mechnikov North-Western State Medical University, Saint-Petersburg, Russia.
[Ti] Title:[Results of open and laparoscopic partial nephrectomy for localized renal cancer].
[So] Source:Urologiia;(6):91-95, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:AIM: To compare the results of laparoscopic and open partial nephrectomy. MATERIALS AND METHODS: From February 2000 to June 2016, 178 patients (mean age 58.2 years) with stage T1 kidney tumors underwent partial nephrectomy. This cohort included 106 (59.5%) men and 72 (40.5%) women. Open partial nephrectomy was performed in 102 (57.3%) patients (group 1) and laparoscopic partial nephrectomy (LPL) - 76 (42.7%, 2nd group). The majority (92.2%) of patients underwent resection for elective and 14 (7.8%) for absolute indications. Preoperatively, 163 (91.6%) and 15 (8.4%) patients had stage T1a stage T1b, respectively. The tumor size ranged from 2.4 to 6.2 cm and from 2 cm to 5.4 cm in group 1 and 2, respectively. A comparative analysis included operative time, warm ischemia time, blood loss, duration of drainage and the length of hospital stay. RESULTS: Open partial nephrectomy was associated with shorter operative time (105 min versus 125 min) and warm ischemia time (14.5 vs. 20.8 min) compared with laparoscopic partial nephrectomy. Laparoscopic partial nephrectomy was characterized by a smaller blood loss (180 ml vs. 365 ml, p<0.05) and a shorter length of hospital stay (2.5 days vs. 5.6 days, p<0.05). One patient from each group was found to have positive surgical margins. CONCLUSION: Currently, laparoscopic partial nephrectomy is the method of choice for stage T1 kidney tumors. Despite the comparatively longer operative time and warm ischemia time, laparoscopic partial nephrectomy leads to faster patient recovery and fewer complications.
[Mh] MeSH terms primary: Blood Loss, Surgical/prevention & control
Kidney Neoplasms/surgery
Kidney/surgery
Laparoscopy/methods
Nephrectomy/methods
[Mh] MeSH terms secundary: Adult
Aged
Female
Follow-Up Studies
Humans
Kidney/pathology
Kidney Neoplasms/pathology
Male
Middle Aged
Retrospective Studies
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  5 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376602
[Au] Autor:Alekseeva GN; Stegnii KV; Pisareva LF; Gurina LI; Volkov MV
[Ad] Address:Pacific State Medical University of Minzdrav of Russia, Vladivostok, Russia.
[Ti] Title:[Improving renal cancer care].
[So] Source:Urologiia;(6):87-90, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:The article reviews the rates of incidence, late diagnosis and mortality from kidney cancer in Primorsky Krai. The authors address the issues of improving primary and specialized medical care by introducing a three-level health care system and restructuring of hospital beds. They propose a new medical technology for assessing the individual risk of kidney cancer and present a program of measures and organizational modules for prevention, early diagnosis and reduction of mortality from kidney cancer.
[Mh] MeSH terms primary: Kidney Neoplasms/diagnosis
Kidney Neoplasms/epidemiology
Kidney Neoplasms/therapy
[Mh] MeSH terms secundary: Female
Humans
Male
Risk Factors
Siberia/epidemiology
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  6 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376589
[Au] Autor:Alyaev YG; Sirota ES; Bezrukov EA; Fiev DN; Bukatov MD; Letunovskii AV; Byadretdinov IS
[Ad] Address:I.M. Sechenov First MSMU of Minzdrav of Russia, Research Institute of Uronephrology and Human Reproductive Health, Moscow, Russia.
[Ti] Title:[Application of 3D soft print models of the kidney for treatment of patients with localized cancer of the kidney (a pilot study)].
[So] Source:Urologiia;(6):12-19, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:AIM: To evaluate the possibility of using 3D-printing in the management of patients with localized kidney cancer. MATERIALS AND METHODS: The study comprised five patients with localized kidney cancer who were treated at the Urology Clinic of the I.M. Sechenov First Moscow State Medical University from January 2016 to April 2017. Along with the standard examination, the patients underwent multispiral computed tomography (MSCT) to produce patient-specific 3D-printed models of the kidney tumors using 3D modeling and 3D printing. To evaluate the effectiveness of using 3D-printed models, two-stage preoperative planning was conducted, and five surgeons were surveyed using a four-question multiple choice questionnaire. At the first stage, the planning of operations was carried out based on MSCT findings. At the second stage, the surgeons were given patient-specific soft 3D models of the kidney with a tumor for preoperative training. After preoperative training, patients underwent laparoscopic resection of the kidney with a tumor. RESULTS: According to the survey results, each of the participating surgeons at least once changed surgical plan based on data obtained with 3D printed models of the kidney with the tumor. The implementation of preoperative training using 3D printed models of the kidney turned out to be effective. All patients underwent laparoscopic surgery performed by a single surgeon with extensive experience in this type of surgery. The mean operative time was 187 minutes. All operations were performed with main renal artery occlusion. The men warm ischemia time was 19.5 minutes and the mean blood loss was 170 ml. There were no conversions to open surgery and organ-removing operations. There were no postoperative complications or deaths. All surgical margins were negative. Morphological examination showed that four patients had renal cell carcinoma one patient had the oncocytoma. CONCLUSION: The study demonstrated the promise of using 3D printing for preoperative planning and surgical performance due to a high-precision three-dimensional soft patient-specific model of the localized kidney.
[Mh] MeSH terms primary: Imaging, Three-Dimensional
Kidney Neoplasms/pathology
Kidney/pathology
Models, Anatomic
Printing, Three-Dimensional
[Mh] MeSH terms secundary: Female
Humans
Kidney/surgery
Kidney Neoplasms/surgery
Male
Pilots
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  7 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29274489
[Au] Autor:Salikov RF; Trainov KP; Belousova IK; Belyy AY; Fatkullina US; Mulyukova RV; Zainullina LF; Vakhitova YV; Tomilov YV
[Ad] Address:N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospect, 119991 Moscow, Russian Federation.
[Ti] Title:Branching tryptamines as a tool to tune their antiproliferative activity.
[So] Source:Eur J Med Chem;144:211-217, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:The influence of a series of tryptamine derivatives on the viability of normal (HEK293) and tumor (HepG2, Jurkat and SH-SY5Y) cells has been evaluated. All tryptamines tested were three different substitution types: C- and N-branching, and indole benzylation. All the derivations enhance the activity of compounds separately, although the effects of different substitutions were not additive. Thus, combinations of C- and N-branchings as well as C-branching and indole benzylation gave little or no increase in activity.
[Mh] MeSH terms primary: Antineoplastic Agents/chemistry
Antineoplastic Agents/pharmacology
Cell Proliferation/drug effects
Tryptamines/chemistry
Tryptamines/pharmacology
[Mh] MeSH terms secundary: Cell Line, Tumor
Cell Survival/drug effects
HEK293 Cells
Humans
Indoles/chemistry
Indoles/pharmacology
Neoplasms/drug therapy
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Indoles); 0 (Tryptamines)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171224
[St] Status:MEDLINE

  8 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29268127
[Au] Autor:Khan I; Garikapati KR; Shaik AB; Makani VKK; Rahim A; Shareef MA; Reddy VG; Pal-Bhadra M; Kamal A; Kumar CG
[Ad] Address:Medicinal Chemistry and Biotechnology Division, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India; Academy of Scientific and Innovative Research, New Delhi 110 025, India.
[Ti] Title:Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis.
[So] Source:Eur J Med Chem;144:104-115, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:A series of 1, 4-dihydroindeno-[1,2-c] pyrazole linked oxindole conjugates have been synthesized by using Knoevenagel condensation method and further evaluated for their antiproliferative activity against HeLa, A549 and MDA-MB-231 human cancer cell lines along with HEK-293 (normal human embryonic kidney cells). Among the derivatives, compounds 12a, 12b, and 12d showed excellent cytotoxicity with IC values ranging between 1.33 to 4.33 µM. Furthermore, detailed biological assays showed that there was accumulation of mitotic cells in G2/M phase, disruption of microtubule network and increase in the G2/M checkpoint proteins (Cyclin B1 and CDK1). Moreover, compound 12d with IC value of 1.33 µM showed significant upregulation of tumor suppressor proteins like p53, p21 and pro-apoptotic Bax. The molecular docking analysis demonstrated that these congeners occupy the colchicine binding pocket of the tubulin.
[Mh] MeSH terms primary: Antineoplastic Agents/chemistry
Antineoplastic Agents/pharmacology
Apoptosis/drug effects
Pyrazoles/chemistry
Pyrazoles/pharmacology
Tubulin Modulators/chemistry
Tubulin Modulators/pharmacology
[Mh] MeSH terms secundary: Cell Line, Tumor
Drug Design
Drug Screening Assays, Antitumor
G2 Phase Cell Cycle Checkpoints/drug effects
HEK293 Cells
HeLa Cells
Humans
Indoles/chemistry
Indoles/pharmacology
Molecular Docking Simulation
Neoplasms/drug therapy
Neoplasms/metabolism
Tubulin/metabolism
Tumor Suppressor Protein p53/metabolism
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Indoles); 0 (Pyrazoles); 0 (Tubulin); 0 (Tubulin Modulators); 0 (Tumor Suppressor Protein p53); 0S9338U62H (2-oxindole)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171222
[St] Status:MEDLINE

  9 / 95770 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29247857
[Au] Autor:Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
[Ad] Address:Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
[Ti] Title:A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
[So] Source:Eur J Med Chem;144:1-28, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Glioblastoma multiforme (GBM) is the most common and deadliest of malignant brain tumors in adults. Disease development is associated with dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway, resulting in increased proliferation; thus, CDK4/6 kinase inhibitors are promising candidates for GBM treatment. The recently developed CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are effective in subcutaneous glioma models, but their blood-brain barrier (BBB) permeability is poor, limiting drug delivery to the central nervous system. Here, we designed and synthesized a series of novel CDK4/6 inhibitors with favorable BBB permeability for the treatment of GBM. Compound 11 exhibited a favorable pharmacological profile and significant penetration of the BBB with the K value of 4.10 and the K value of 0.23 in mice after an oral dose of 10 mg/kg. IC values for CDK4/cyclin D1 and CDK6/cyclin D3 were 3 nM and 1 nM, respectively. In vivo studies with an orthotopic xenograft mouse model of GBM showed that 11 had tumor growth inhibition values ranging from 62% to 99% for doses ranging from 3.125 to 50 mg/kg, and no significant body weight loss was observed. The increase in life span based on the median survival time of vehicle-treated animals in mice administered a dose of 50 mg/kg was significant at 162% (p < 0.0001). These results suggest that compound 11 is a promising candidate for further investigation as an effective drug for the treatment of GBM.
[Mh] MeSH terms primary: Brain Neoplasms/drug therapy
Cyclin-Dependent Kinase 4/antagonists & inhibitors
Cyclin-Dependent Kinase 6/antagonists & inhibitors
Drug Design
Glioblastoma/drug therapy
Protein Kinase Inhibitors/pharmacokinetics
Protein Kinase Inhibitors/therapeutic use
[Mh] MeSH terms secundary: Animals
Blood-Brain Barrier/metabolism
Blood-Brain Barrier/pathology
Brain Neoplasms/metabolism
Brain Neoplasms/pathology
Cell Line, Tumor
Cyclin-Dependent Kinase 4/metabolism
Cyclin-Dependent Kinase 6/metabolism
Dogs
Glioblastoma/metabolism
Glioblastoma/pathology
Humans
Madin Darby Canine Kidney Cells
Male
Mice
Protein Kinase Inhibitors/chemistry
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Protein Kinase Inhibitors); EC 2.7.11.22 (Cyclin-Dependent Kinase 4); EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171217
[St] Status:MEDLINE

  10 / 95770 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29228125
[Au] Autor:Wu B; Ingersoll K; Jug R; Yang LH; Luedke C; Lo A; Su P; Liu X; Rehder C; Gong J; Lu CM; Wang E
[Ad] Address:Division of Hematology, Department of Medicine, Shengjing Hospital affiliated to China Medical University, Shenyang, China.
[Ti] Title:Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
[So] Source:Am J Clin Pathol;149(1):55-66, 2017 Dec 20.
[Is] ISSN:1943-7722
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives: Myeloid neoplasms (MNs) after solid organ transplant are rare, and their clinicopathologic features have not been well characterized. Methods: We retrospectively analyzed 23 such cases. Results: The ages ranged from 2 to 76 years, with a median of 59 years at the diagnosis. The median interval between the transplant and diagnosis was 56 months (range, 8-384 months). The transplanted organs included liver in five, kidney in six, lung in five, heart in six, and heart/lung in one case(s). The types of MN included acute myeloid leukemia (AML) in 12, myelodysplastic syndrome (MDS) in five, chronic myelogenous leukemia (CML) in four, and myeloproliferative neoplasms (MPNs) in two cases. Cytogenetics demonstrated clonal abnormalities in 18 (78.3%) cases, including unbalanced changes in 10 (55.6%), Philadelphia chromosome in four (22.2%), and other balanced aberrations in four (22.2%) cases. Thirteen (56.5%) patients died, with an estimated median survival of 9 months. With disease stratification, AML and MDS have short median survivals (3.5 and 7 months, respectively), with an initial precipitous decline of the survival curve. Conclusions: Posttransplant MNs have a latency period between that seen in AML/MDS related to alkylators and that associated with topoisomerase II inhibitors. The cytogenetic profile suggests a mutagenic effect on leukemogenesis. The clinical outcome for AML/MDS is dismal, with death occurring at an early phase of treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/ajcp/aqx133


page 1 of 9577 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information